Skip to main content
Erschienen in: Journal of Cardiovascular Translational Research 2/2020

06.11.2019 | Original Article

Atrial Fibrillation Is Associated with Recurrent Ventricular Arrhythmias After LVAD Implant: Incidence and Impact in a Consecutive Series

verfasst von: Kathleen T. Hickey, Paolo C. Colombo, Yoshifumi Naka, Arthur R. Garan, Melana Yuzefpolskaya, Hasan Garan, Elaine Y. Wan, Robert R. Sciacca, Isaac Goldenthal, Angelo B. Biviano

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

This study examined left-ventricular assist device (LVAD) patients with pre-LVAD ventricular arrhythmias (VAs) to determine the rate of recurrent post-LVAD VAs and the impact of pre-LVAD atrial fibrillation (AF) on recurrent post-LVAD VAs. Medical records of 195 consecutive LVAD patients were reviewed. Descriptive statistics were generated and Cox proportional hazard models were used to assess the association of clinical variables with the time to recurrent VA. Forty-seven percent of 195 CHF patients who received LVAD-manifested significant VAs prior to LVAD implant (82% Heartmate II, 14% HVAD, 4% other; median follow-up = 17 months), 41% of whom manifested recurrent post-LVAD VAs. Pre-LVAD AF was associated with recurrent VAs (hazard ratio = 3.73; 95% CI 1.33, 10.48; p = 0.012). Recurrent VAs were associated with increased mortality (hazard ratio = 3.06; 95% CI 1.17, 7.98; p = 0.023). A history of AF is prevalent in over half of LVAD patients with recurrent VAs and is associated with time to recurrence of VA.
Literatur
1.
Zurück zum Zitat Enriquez, A. D., et al. (2014). Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. Journal of the American College of Cardiology, 64(18), 1883–1890.CrossRef Enriquez, A. D., et al. (2014). Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. Journal of the American College of Cardiology, 64(18), 1883–1890.CrossRef
2.
Zurück zum Zitat Brenyo, A., et al. (2012). Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. Journal of Cardiovascular Electrophysiology, 23(5), 515–520.CrossRef Brenyo, A., et al. (2012). Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. Journal of Cardiovascular Electrophysiology, 23(5), 515–520.CrossRef
3.
Zurück zum Zitat Oswald, H., et al. (2010). Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. European Journal of Heart Failure, 12(6), 593–599.CrossRef Oswald, H., et al. (2010). Implantable defibrillator therapy for ventricular tachyarrhythmia in left ventricular assist device patients. European Journal of Heart Failure, 12(6), 593–599.CrossRef
4.
Zurück zum Zitat Andersen, M., et al. (2009). Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). The Journal of Heart and Lung Transplantation, 28(7), 733–735.CrossRef Andersen, M., et al. (2009). Incidence of ventricular arrhythmias in patients on long-term support with a continuous-flow assist device (HeartMate II). The Journal of Heart and Lung Transplantation, 28(7), 733–735.CrossRef
5.
Zurück zum Zitat Garan, A. R., et al. (2013). Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? Journal of the American College of Cardiology, 61(25), 2542–2550.CrossRef Garan, A. R., et al. (2013). Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? Journal of the American College of Cardiology, 61(25), 2542–2550.CrossRef
6.
Zurück zum Zitat Hickey, K. T., et al. (2016). Atrial fibrillation in patients with left ventricular assist devices: Incidence, Predictors, and Clinical Outcomes. JACC: Clinical Electrophysiology, 2(7), 793–798.PubMed Hickey, K. T., et al. (2016). Atrial fibrillation in patients with left ventricular assist devices: Incidence, Predictors, and Clinical Outcomes. JACC: Clinical Electrophysiology, 2(7), 793–798.PubMed
7.
Zurück zum Zitat Efimova, E., et al. (2017). Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm, 14(12), 1812–1819.CrossRef Efimova, E., et al. (2017). Predictors of ventricular arrhythmia after left ventricular assist device implantation: a large single-center observational study. Heart Rhythm, 14(12), 1812–1819.CrossRef
8.
Zurück zum Zitat Refaat, M., et al. (2008). Ventricular arrhythmias after left ventricular assist device implantation. Pacing and Clinical Electrophysiology, 31(10), 1246–1252.CrossRef Refaat, M., et al. (2008). Ventricular arrhythmias after left ventricular assist device implantation. Pacing and Clinical Electrophysiology, 31(10), 1246–1252.CrossRef
9.
Zurück zum Zitat Kadado, A. J., Akar, J. G., & Hummel, J. P. (2018). Arrhythmias after left ventricular assist device implantation: incidence and management. Trends in Cardiovascular Medicine, 28(1), 41–50.CrossRef Kadado, A. J., Akar, J. G., & Hummel, J. P. (2018). Arrhythmias after left ventricular assist device implantation: incidence and management. Trends in Cardiovascular Medicine, 28(1), 41–50.CrossRef
11.
Zurück zum Zitat Hottigoudar, R. U., et al. (2013). Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congestive Heart Failure, 19(4), 165–171.CrossRef Hottigoudar, R. U., et al. (2013). Catheter ablation of atrial flutter in patients with left ventricular assist device improves symptoms of right heart failure. Congestive Heart Failure, 19(4), 165–171.CrossRef
12.
Zurück zum Zitat Somberg, J. C., et al. (2004). Enhancement of myocardial vulnerability by atrial fibrillation. American Journal of Therapeutics, 11(1), 33–43.CrossRef Somberg, J. C., et al. (2004). Enhancement of myocardial vulnerability by atrial fibrillation. American Journal of Therapeutics, 11(1), 33–43.CrossRef
13.
Zurück zum Zitat Kotecha, D., et al. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885–2896.CrossRef Kotecha, D., et al. (2017). Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology, 69(24), 2885–2896.CrossRef
14.
Zurück zum Zitat Packer, D. L., et al. (2018). Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. American Heart Journal, 199, 192–199.CrossRef Packer, D. L., et al. (2018). Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. American Heart Journal, 199, 192–199.CrossRef
15.
Zurück zum Zitat Bardy, G. H., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.CrossRef Bardy, G. H., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225–237.CrossRef
16.
Zurück zum Zitat Moss, A. J., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England Journal of Medicine, 361(14), 1329–1338.CrossRef Moss, A. J., et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. The New England Journal of Medicine, 361(14), 1329–1338.CrossRef
17.
Zurück zum Zitat Moss, A. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.CrossRef Moss, A. J., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346(12), 877–883.CrossRef
18.
Zurück zum Zitat Makki, N., et al. (2015). Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. The American Journal of Cardiology, 116(9), 1385–1390.CrossRef Makki, N., et al. (2015). Meta-analysis of the relation of ventricular arrhythmias to all-cause mortality after implantation of a left ventricular assist device. The American Journal of Cardiology, 116(9), 1385–1390.CrossRef
19.
Zurück zum Zitat Kirklin, J. K., et al. (2017). Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation, 36(10), 1080–1086.CrossRef Kirklin, J. K., et al. (2017). Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation, 36(10), 1080–1086.CrossRef
20.
Zurück zum Zitat Enriquez, A. D., et al. (2013). The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circulation. Arrhythmia and Electrophysiology, 6(4), 668–674.CrossRef Enriquez, A. D., et al. (2013). The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circulation. Arrhythmia and Electrophysiology, 6(4), 668–674.CrossRef
Metadaten
Titel
Atrial Fibrillation Is Associated with Recurrent Ventricular Arrhythmias After LVAD Implant: Incidence and Impact in a Consecutive Series
verfasst von
Kathleen T. Hickey
Paolo C. Colombo
Yoshifumi Naka
Arthur R. Garan
Melana Yuzefpolskaya
Hasan Garan
Elaine Y. Wan
Robert R. Sciacca
Isaac Goldenthal
Angelo B. Biviano
Publikationsdatum
06.11.2019
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 2/2020
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-019-09914-0

Weitere Artikel der Ausgabe 2/2020

Journal of Cardiovascular Translational Research 2/2020 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.